keyword
MENU ▼
Read by QxMD icon Read
search

dyslipidemia and coenzyme Q10

keyword
https://www.readbyqxmd.com/read/27157250/the-effects-of-a-nutraceutical-combination-on-plasma-lipids-and-glucose-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#1
REVIEW
Matteo Pirro, Massimo Raffaele Mannarino, Vanessa Bianconi, Luis E Simental-Mendía, Francesco Bagaglia, Elmo Mannarino, Amirhossein Sahebkar
Dyslipidemia and hyperglycemia are associated with an increased risk of ischemic cardiovascular disease. Positive effects of a nutraceutical combination comprising red yeast rice, berberine, policosanol, astaxanthin, coenzyme Q10 and folic acid (NComb) on plasma lipid and glucose levels have been reported in some but not all clinical trials. To address this inconsistency, we tried to estimate the size of lipid- and glucose-lowering effects of NComb through a systematic review and meta-analysis of randomized controlled trials...
August 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/26897092/statin-associated-cerebellar-ataxia-a-brazilian-case-series
#2
Hélio A G Teive, Adriana Moro, Mariana Moscovich, Walter O Arruda, Renato Puppi Munhoz
BACKGROUND: Drug-induced cerebellar ataxias (DICA) represent an important group of secondary cerebellar ataxias. Herein, we reported a case series of progressive cerebellar ataxia induced by HMG-CoA reductase inhibitors (statins). METHODS: Observational study with a Brazilian case series of patients with cerebellar ataxia due to statins use. RESULTS: We described four patients with cerebellar ataxia, predominantly gait ataxia, due to statins use...
April 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/26611120/usefulness-of-nutraceuticals-armolipid-plus-versus-ezetimibe-and-combination-in-statin-intolerant-patients-with-dyslipidemia-with-coronary-heart-disease
#3
RANDOMIZED CONTROLLED TRIAL
Giuseppe Marazzi, Francesco Pelliccia, Giuseppe Campolongo, Silvia Quattrino, Luca Cacciotti, Maurizio Volterrani, Carlo Gaudio, Giuseppe Rosano
Statins are extensively used to treat dyslipidemia, but, because of their low tolerability profile, they are discontinued in a significant proportion of patients. Ezetimibe and nutraceuticals have been introduced as alternative therapies and have proved to be effective and well tolerated. A single-blind, single-center, randomized, prospective, and parallel group trial comparing a combination of nutraceuticals (red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin), called Armolipid Plus, and ezetimibe for 3 months in terms of efficacy and tolerability...
December 15, 2015: American Journal of Cardiology
https://www.readbyqxmd.com/read/26604775/reversal-of-statin-induced-memory-dysfunction-by-co-enzyme-q10-a-case-report
#4
Basil N Okeahialam
Statins are useful in the armamentarium of the clinician dealing with dyslipidemia, which increases cardiovascular morbi-mortality in hypertensive and diabetic patients among others. Dyslipidemia commonly exists as a comorbidity factor in the development of atherosclerotic cardiovascular disease. Use of statins is however associated with side effects which at times are so disabling as to interfere with activities of daily living. There are various ways of dealing with this, including use of more water-soluble varieties, intermittent dosing, or use of statin alternatives...
2015: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/24528686/nutraceutical-approach-to-moderate-cardiometabolic-risk-results-of-a-randomized-double-blind-and-crossover-study-with-armolipid-plus
#5
RANDOMIZED CONTROLLED TRIAL
Massimiliano Ruscica, Monica Gomaraschi, Giuliana Mombelli, Chiara Macchi, Raffaella Bosisio, Franco Pazzucconi, Chiara Pavanello, Laura Calabresi, Anna Arnoldi, Cesare R Sirtori, Paolo Magni
BACKGROUND: Primary cardiovascular prevention may be achieved by lifestyle/nutrition improvements and specific drugs, although a relevant role is now emerging for specific functional foods and nutraceuticals. OBJECTIVES: The aim of this study was to evaluate the usefulness of a nutraceutical multitarget approach in subjects with moderate cardiovascular risk and to compare it with pravastatin treatment. SUBJECTS: Thirty patients with moderate dyslipidemia and metabolic syndrome (according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) were included in an 8-week randomized, double-blind crossover study and took either placebo or a nutraceutical combination that contained red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid (Armolipid Plus)...
January 2014: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/23018482/use-of-a-lipid-lowering-food-supplement-in-patients-on-hormone-therapy-following-breast-cancer
#6
M Zanardi, E Quirico, C Benvenuti, A Pezzana
AIM: The aim of this paper was to determine the activity of a natural nutraceuticals combination (AP=Berberine+Red Yeast Rice) on dyslipidemia which frequently persists after life style changes in patients on hormone-therapy following breast cancer (HT-BC). METHODS: Twenty-one HT-BC patients, free of tumor, mean age 59.9 years, BMI 28,9 kg/m2, waist circumference 95.9 cm, with altered lipid profile (total cholesterol 269.0 mg/dL, high-density lipoprotein (HDL) cholesterol 54...
October 2012: Minerva Ginecologica
https://www.readbyqxmd.com/read/22120862/statin-intolerance-now-a-solved-problem
#7
REVIEW
P Sikka, S Kapoor, V K Bindra, M Sharma, P Vishwakarma, K K Saxena
Statins are the most effective and widely used drugs for treating dyslipidemia, a major risk factor for coronary heart disease. These are one of the safest hypolipidemic drugs but many patients are bound to discontinue statins due to their side effects. Hepatotoxicity, myotoxicity and peripheral neuropathy are important out of them. Discontinuation of statins leads to dylipidemia and its grave consequences. Hence, there should be enough strategies for statin intolerant patients, so that they can be saved from these consequences...
October 2011: Journal of Postgraduate Medicine
https://www.readbyqxmd.com/read/22113535/long-term-effects-of-nutraceuticals-berberine-red-yeast-rice-policosanol-in-elderly-hypercholesterolemic-patients
#8
RANDOMIZED CONTROLLED TRIAL
Giuseppe Marazzi, Luca Cacciotti, Francesco Pelliccia, Luigi Iaia, Maurizio Volterrani, Giuseppe Caminiti, Barbara Sposato, Rosalba Massaro, Fabrizia Grieco, Giuseppe Rosano
INTRODUCTION: Statins are at the forefront of strategies to manage dyslipidemia, although they are not always well tolerated. At 6-7 months after the drug was supplied, discontinuation rates averaged 30%. Alternate agents to statins have been studied. Some nutraceuticals demonstrated an efficacy in reducing cholesterol concentrations. However, there are no data regarding the use of nutraceuticals in elderly dyslipidemic patients. The purpose of this study was to examine the efficacy, safety, and tolerability of a nutraceutical-based protocol in elderly hypercholesterolemic patients previously intolerant to statins...
December 2011: Advances in Therapy
https://www.readbyqxmd.com/read/21868014/mechanisms-of-statin-induced-myalgia-assessed-by-physiogenomic-associations
#9
MULTICENTER STUDY
Gualberto Ruaño, Andreas Windemuth, Alan H B Wu, John P Kane, Mary J Malloy, Clive R Pullinger, Mohan Kocherla, Kali Bogaard, Bruce R Gordon, Theodore R Holford, Ankur Gupta, Richard L Seip, Paul D Thompson
OBJECTIVE: We investigated genetic variants predictive of muscular side effects in patients treated with statins. We utilized a physiogenomic approach to prototype a multi-gene panel correlated with statin-induced myalgia. BACKGROUND: Statin-induced myalgia occurs in ∼10% of lipid clinic outpatients. Its clinical manifestation may depend in part upon gene variation from patient to patient. METHODS: We genotyped 793 patients (377 with myalgia and 416 without) undergoing statin therapy at four U...
October 2011: Atherosclerosis
https://www.readbyqxmd.com/read/21591387/-assessment-of-quality-of-life-after-inclusion-of-coenzyme-q10-in-the-scheme-of-treatment-of-women-with-arterial-hypertension-and-elevated-risk-of-cardiovascular-complications
#10
COMPARATIVE STUDY
https://www.readbyqxmd.com/read/21368390/effects-of-carnitine-and-coenzyme-q10-on-lipid-profile-and-serum-levels-of-lipoprotein-a-in-maintenance-hemodialysis-patients-on-statin-therapy
#11
RANDOMIZED CONTROLLED TRIAL
Mirhatef Shojaei, Mahmoud Djalali, Mohammadreza Khatami, Fereydoun Siassi, Mohammadreza Eshraghian
INTRODUCTION: Dyslipidemia and high serum lipoprotein(a) are among the risk factors for cardiovascular diseases in hemodialysis patients. Statins as a first line of therapy in hyperlipidemia does not always reduce the serum lipoprotein(a) level. Several studies have reported the lipid-lowering effects of carnitine and coenzyme Q10 in hemodialysis patients. This study was designed to investigate the effects of carnitine and coenzyme Q10 on serum lipid profile and lipoprotein(a) level in maintenance hemodialysis patients...
March 2011: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/20628837/evidence-based-management-of-statin-myopathy
#12
REVIEW
Charles R Harper, Terry A Jacobson
Statin-associated muscle symptoms are a relatively common condition that may affect 10% to 15% of statin users. Statin myopathy includes a wide spectrum of clinical conditions, ranging from mild myalgia to rhabdomyolysis. The etiology of myopathy is multifactorial. Recent studies suggest that statins may cause myopathy by depleting isoprenoids and interfering with intracellular calcium signaling. Certain patient and drug characteristics increase risk for statin myopathy, including higher statin doses, statin cytochrome metabolism, and polypharmacy...
September 2010: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/20196891/support-of-drug-therapy-using-functional-foods-and-dietary-supplements-focus-on-statin-therapy
#13
Simone Eussen, Olaf Klungel, Johan Garssen, Hans Verhagen, Henk van Kranen, Henk van Loveren, Cathy Rompelberg
Functional foods and dietary supplements might have a role in supporting drug therapy. These products may (1) have an additive effect to the effect that a drug has in reducing risk factors associated with certain conditions, (2) contribute to improve risk factors associated with the condition, other than the risk factor that the drug is dealing with, or (3) reduce drug-associated side effects, for example, by restoring depleted compounds or by reducing the necessary dose of the drug. Possible advantages compared with a multidrug therapy are lower drug costs, fewer side effects and increased adherence...
May 2010: British Journal of Nutrition
https://www.readbyqxmd.com/read/19705518/the-effects-of-omega-3-fatty-acids-and-coenzyme-q10-on-blood-pressure-and-heart-rate-in-chronic-kidney-disease-a-randomized-controlled-trial
#14
RANDOMIZED CONTROLLED TRIAL
Trevor A Mori, Valerie Burke, Ian Puddey, Ashley Irish, Christine A Cowpland, Lawrence Beilin, Gursharan Dogra, Gerald F Watts
BACKGROUND AND OBJECTIVE: Chronic kidney disease (CKD) associates with increased cardiovascular disease (CVD) risk. Hypertension is a major determinant of progression of CKD. Omega-3 fatty acids (omger3FA) protect against CVD via improvements in blood pressure, heart rate, vascular reactivity and serum lipids. Coenzyme Q(10) (CoQ) may improve blood pressure and vascular function. This study determined whether omega3FA and CoQ have independent or additive effects in improving the cardiovascular profile, particularly blood pressure and heart rate, in nondiabetic patients with CKD stages 3-4...
September 2009: Journal of Hypertension
https://www.readbyqxmd.com/read/19649137/plasma-coenzyme-q10-predicts-lipid-lowering-response-to-high-dose-atorvastatin
#15
Michael A Pacanowski, Reginald F Frye, Osatohanmen Enogieru, Richard S Schofield, Issam Zineh
BACKGROUND: Coenzyme Q10 (CoQ10) is a provitamin synthesized via the HMG-CoA reductase pathway, and thus may serve as a potential marker of intrinsic HMG-CoA reductase activity. HMG-CoA reductase inhibitors (statins) decrease CoQ10, although it is unclear whether this is due to reductions in lipoproteins, which transport CoQ10. OBJECTIVES: We evaluated whether baseline plasma CoQ10 concentrations predict the lipid-lowering response to high-dose atorvastatin, and to what extent CoQ10 changes following atorvastatin therapy depend on lipoprotein changes...
August 2008: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/18544898/beneficial-effect-of-coenzyme-q10-on-increased-oxidative-and-nitrative-stress-and-inflammation-and-individual-metabolic-components-developing-in-a-rat-model-of-metabolic-syndrome
#16
Masaru Kunitomo, Yu Yamaguchi, Satomi Kagota, Kazumasa Otsubo
Metabolic syndrome (MetS) is a group of cardiovascular risk factors, including visceral obesity, glucose intolerance, hypertension, and dyslipidemia. Increased oxidative and nitrative stress and inflammation and decreased endothelial function occur in an animal model of metabolic syndrome, SHR/NDmcr-cp (SHR/cp) rats. The present study investigated the effects of coenzyme Q10 (CoQ10), one of the important antioxidants, on the abnormal oxidative condition and characteristic components of metabolic syndrome in SHR/cp rats by maintaining them on a diet supplemented with 0...
June 2008: Journal of Pharmacological Sciences
https://www.readbyqxmd.com/read/17620856/the-broad-spectrum-of-statin-myopathy-from-myalgia-to-rhabdomyolysis
#17
REVIEW
Charles R Harper, Terry A Jacobson
PURPOSE OF REVIEW: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are the cornerstone of therapy for dyslipidemia. A significant portion of patients are not adherent to statin therapy, due to either intolerance from muscle symptoms or fears of myopathy reported in the media. The diagnosis and management of patients with statin-induced myopathy will be reviewed. RECENT FINDINGS: Based on a review of healthy clinical-trial participants, the placebo-corrected incidences of minor muscle pain, myopathy (with significant elevations in creatinine kinase), and rhabdomyolysis are 190, 5, and 1...
August 2007: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/16827283/-experience-in-coenzyme-q10-application-in-complex-therapy-of-coronary-heart-disease-with-dyslipidemia
#18
O L Belaia, V I Kalmykova, L A Ivanova, L G Kochergina
The subjects of the study were 43 patients with II- III functional class coronary heart disease (CHD) and dyslipidemia, who received conventional cardial therapy. The patients were divided into two groups: group I (26 subjects) received vasilip, a simvastatin generic, in a dose of 20 mg a day; group 11 (17 subjects) received vasilip in a dose of 20 mg a day plus cudesan in a dose of 1 ml a day, which contained 30 mg of ubiquinone Q 10 and 4.5 mg of alpha-tocopherol. Effects of the therapies on blood lipids, their peroxides, and the antioxidative status of blood were studied...
2006: Klinicheskaia Meditsina
https://www.readbyqxmd.com/read/15932792/possible-role-of-ubiquinone-in-the-treatment-of-massive-hypertriglyceridemia-resistant-to-pufa-and-fibrates
#19
COMPARATIVE STUDY
A F G Cicero, G Derosa, A Miconi, L Laghi, S Nascetti, A Gaddi
OBJECTIVE: To describe the effect of Coenzyme Q10 (CoQ10) (added to either a fibrate, or polyunsaturated fatty acids (PUFA) or association of both) in patients affected by massive hypertriglyceridemia (MHTG) resistant to fibrates and PUFA. DESIGN: Open, sequential, comparative intervention study. SETTING: Specialised centres for dyslipidemia management. SUBJECTS: Fifteen subjects (mean age: 45.1+/-12.5 years) affected by MHTG and hyporesponsive to either fibrates, or PUFA, or fibrates-PUFA association, and 15 age-matched subjects regularly responders to PUFA and fenofibrate treatment...
July 2005: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/15817994/treatment-of-massive-hypertriglyceridemia-resistant-to-pufa-and-fibrates-a-possible-role-for-the-coenzyme-q10
#20
A F G Cicero, G Derosa, A Miconi, L Laghi, S Nascetti, A Gaddi
OBJECTIVE: To describe the effect of CoQ10 (added to either a fibrate, or PUFA or association of both) in patients affected by massive hypertriglyceridemia (MHTG) resistant to fibrates and PUFA. DESIGN: Open, sequential, comparative intervention study. SETTING: Specialised centres for dyslipidemia management. SUBJECTS: 15 subjects (mean age: 45.1 +/- 12.5 years) affected by MHTG and hyporesponsive to either fibrates, or PUFA, or fibrates-PUFA association, and 15 age-matched subjects regularly responders to PUFA and fenofibrate treatment...
2005: BioFactors
keyword
keyword
74702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"